Przegląd Menopauzalny

Abstract

2/2024 vol. 23
Original paper

Optimising antidiabetic medication management for type 2 diabetes and renal dysfunction in Can Tho City, Vietnam

  1. Faculty of Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
  2. Department of Medicinal Chemistry-Pharmacology-Clinical Pharmacy, Pham Ngoc Thach College, Can Tho City, Vietnam
Menopause Rev 2024; 23(2): 75-82
Online publish date: 2024/07/04
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

The research aimed to delineate and investigate the utilisation of antidiabetic drugs in type 2 diabetes patients with kidney failure at a hospital in Can Tho City, Vietnam.

Material and methods

The research analysed the use of antidiabetic drugs at various time points, determined the drug interaction rate, and evaluated the appropriate use of drugs and the relationship with the achievement of target blood glucose and HbA1c levels. A two-tailed Student’s t-test was employed to compare continuous variables, an ANOVA test was used to assess multiple values, and an 2 test was utilised to evaluate categorical variables.

Results

Insulin monotherapy was the predominant regimen for treating type 2 diabetes in patients with impaired kidney function. Metformin was the most prescribed oral medication. Approximately 85.78% of patients received safe and appropriate diabetes treatment. Statistical analysis revealed a significant relationship between achieving target blood glucose and HbA1c after 3 months and factors such as safe drug use and minimal drug interactions (p < 0.05). Patients with chronic kidney disease demonstrated better blood glucose control compared to those with acute kidney disease.

Conclusions

The most common drug used for type 2 diabetes patients with impaired kidney function was insulin monotherapy, with usage increasing with the severity of chronic kidney disease. The chronic kidney disease group exhibited a higher rate of achieving target blood glucose and HbA1c compared to the acute kidney disease group. Rational, safe, and interaction-free drug use significantly contributed to better blood sugar control compared to less prudent medication choices.

Share
without publication fees